| Literature DB >> 26992705 |
Ana Filipa Sobral1, Cristina Amaral2, Georgina Correia-da-Silva3, Natércia Teixeira4.
Abstract
Aromatase inhibitors (AIs) are anti-tumor agents used in clinic to treat hormone-dependent breast cancer. AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation steroidal AI, belongs to this class of drugs and is currently used in clinic to treat postmenopausal women, due to its high efficacy and good tolerability. Here, its pharmacological and biological aspects as well as its clinical applications and comparison to other endocrine therapeutic agents, are reviewed. It is also focused the benefits and risks of exemestane, drawbacks to be overcome and aspects to be explored.Entities:
Keywords: Aromatase inhibitors; Clinical trials; Endocrine resistance; Endocrine therapy; Exemestane; Hormone-dependent breast cancer
Mesh:
Substances:
Year: 2016 PMID: 26992705 DOI: 10.1016/j.jsbmb.2016.03.019
Source DB: PubMed Journal: J Steroid Biochem Mol Biol ISSN: 0960-0760 Impact factor: 4.292